menu
    • menu
    [{"orgOrder":0,"company":"Desentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DM-101","moa":"IgE","graph1":"Immunology","graph2":"Phase II","graph3":"Desentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Desentum \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Desentum \/ Undisclosed"},{"orgOrder":0,"company":"Desentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DM-101","moa":"IgE","graph1":"Immunology","graph2":"Phase I","graph3":"Desentum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Desentum \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Desentum \/ Undisclosed"},{"orgOrder":0,"company":"Desentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DM-101PX","moa":"IgE","graph1":"Immunology","graph2":"Phase I","graph3":"Desentum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Desentum \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Desentum \/ Undisclosed"},{"orgOrder":0,"company":"Desentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DM-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Desentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Desentum \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Desentum \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Desentum

    Menu

    Desentum

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Desentum

                            Finland arrow
                            Global ChemShow
                            Not Confirmed

                            Desentum

                            Finland arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DM-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety and Efficacy of DM-101PX in Adults With Birch Pollen Allergy

                            Details : DM-101 is a vaccine drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Birch Pollen Allergy.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 28, 2025

                            Lead Product(s) : DM-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Desentum

                            Finland arrow
                            Global ChemShow
                            Not Confirmed

                            Desentum

                            Finland arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DM-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Desentum Reports Strong Phase 1 Data for Birch Pollen Allergy Vaccine DM-101PX

                            Details : DM-101PX is an investigational medicinal product for immunotherapeutic treatment of birch pollen allergy. The active ingredient DM-101 is a recombinant variant of major birch pollen allergen.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 02, 2025

                            Lead Product(s) : DM-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Desentum

                            Finland arrow
                            Global ChemShow
                            Not Confirmed

                            Desentum

                            Finland arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DM-101PX

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participa...

                            Details : DM-101PX is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Birch Pollen Allergy.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 14, 2023

                            Lead Product(s) : DM-101PX

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Desentum

                            Finland arrow
                            Global ChemShow
                            Not Confirmed

                            Desentum

                            Finland arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DM-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

                            Details : DM-101 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Birch Pollen Allergy.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 12, 2020

                            Lead Product(s) : DM-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth